Human integrin αVβ5 (vitronectin receptor; ITGAV / ITGB5, CD51/CD61-family, alias VNRA, MSK8), affinity-purified from human placenta and supplied lyophilised, 5 µg. The purified heterodimer runs as two major bands under non-reducing conditions, corresponding to the αV (145 kDa) and β5 (90 kDa) subunits. αVβ5 is an RGD-binding integrin that mediates cell adhesion to vitronectin and participates in TGF-β activation, angiogenesis and phagocytosis of apoptotic cells. Supplied as a defined standard for electrophoresis, immunoblotting and ligand-binding studies; it is the companion product to the fibronectin receptor α5β1 cat. 638, and is complemented by the integrin β3 antibody cat. 879 and the integrin αIIb (CD41) antibody cat. 424.
SPECIFICATIONS
Catalogue number: 476 | Product: Integrin αVβ5 (human)
Source: human placenta. The product was tested and found negative for HIV and Hepatitis B
Gene: ITGAV / ITGB5 | Aliases: CD51, VNRA, MSK8, alphaVbeta5
Purity: at least 95% by SDS-PAGE with silver staining; two major bands corresponding to the αV (145 kDa) and β5 (90 kDa) subunits under non-reducing conditions
Purification: affinity chromatography on immobilised monoclonal anti-αVβ5 antibodies; the tissue detergent extract applied to the column was prepared as described in Belkin et al. 1990
Format: lyophilized from a solution containing 0.26 mg/mL αVβ5, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM MgCl2, 0.2% Triton X-100
Package size: 5 µg
STORAGE / RECONSTITUTION
Reconstitute in water.
Lyophilized product: ships at ambient temperature; store long-term at −20 °C.
Reconstituted protein: store at −70 °C (stable for 1 year).
Avoid repeated freeze-thaw cycles of reconstituted material.
APPLICATIONS
- Molecular-weight and identity standard for SDS-PAGE / electrophoresis of integrin heterodimers.
- Positive control and standard for immunoblotting (Western blot) of integrin αV and β5 subunits — pair with cat. 879 when probing the β3/β-subunit family.
- Solid-phase ligand-binding assays with RGD-containing ligands (vitronectin, fibronectin, osteopontin, latent TGF-β LAP).
- Coating antigen for integrin ELISA and antibody-characterisation work.
- Immunogen and screening antigen for the generation of anti-integrin antibodies.
APPLICATION HIGHLIGHTS — HIGH-VALUE RESEARCH NICHES
- RGD-mimetic and integrin-antagonist drug discovery: purified receptor for competitive ligand-binding and inhibitor IC50 screening.
- TGF-β activation biology: αVβ5 is a principal latent-TGF-β activating integrin, central to fibrosis research.
- Tumour angiogenesis and metastasis: αVβ5 is upregulated on angiogenic endothelium and many carcinomas.
- Adenoviral and viral-entry studies, where αVβ5 acts as an internalisation co-receptor.
- Efferocytosis and retinal-pigment-epithelium phagocytosis assays.
- Biomaterial and RGD-peptide surface characterisation for regenerative-medicine scaffolds.
REFERENCES
Belkin VM, Belkin AM, Koteliansky VE. Human smooth muscle VLA-1 integrin: purification, substrate specificity, localization in aorta, and expression during development. J Cell Biol. 1990;111(5 Pt 1):2159–2170. doi:10.1083/jcb.111.5.2159. PMID: 2172263. (Source of the tissue detergent-extract preparation used for affinity purification.)
